SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-059539
Filing Date
2024-05-14
Accepted
2024-05-14 16:09:36
Documents
13
Period of Report
2024-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20240513.htm   iXBRL 8-K 56157
2 EX-99.1 tnya-ex99_1.htm EX-99.1 99049
3 GRAPHIC img92481827_0.jpg GRAPHIC 6181
  Complete submission text file 0000950170-24-059539.txt   296727

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240513.xsd EX-101.SCH 28125
16 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240513_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 24944376
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)